Status:
UNKNOWN
Outcomes for Patients With Gastro-Esophageal Reflux Disease
Lead Sponsor:
Tianjin Happy Life Technology Co., Ltd.
Conditions:
Gastro-esophageal Reflux Disease
Eligibility:
All Genders
Brief Summary
Gastro-esophageal reflux disease (GERD), the most common cause of erosive esophagitis (EE), remains highly prevalent worldwide. GERD poses substantial burden on both patients and society. EE treatmen...
Eligibility Criteria
Inclusion
- Medical records of GERD, NERD and/or EE diagnoses （ICD code scope will be confirmed later）from January 1st, 2015 to December 31st, 2017.
- oGERD is typically characterized by symptoms of heartburn and acid regurgitation. A diagnosis of EE or NERD can only be confirmed upon endoscopic examination.
- All ages, males or females
- A primary diagnosis of GERD/NERD/EE
- For treatment patterns, patients are also required to have received one episode of treatment during the analysis period.
- For RW treatment efficacy, the population will be restricted to the EE treatment population who underwent at least two endoscopy examinations.
Exclusion
- \- No exclusion criteria will be applied for investigating diagnosis since all patients diagnosed with GERD, NERD, or EE should be captured regardless of whether they have medical conditions that affect their treatments.
- A patient will not be eligible for investigating treatment patterns and RW treatment efficacy if he/she has any of the following exclusion criterion:
- A post-operative diagnosis of gastrointestinal cancers
- A diagnosis of esophageal foreign bodies or neoplasms
- A history of gastric or esophageal surgery
- Zollinger-Ellison syndrome
- Primary esophageal motility disorders (ex: achalasia)
- Esophageal strictures
- Eosinophilic esophagitis
- Identified as pregnant or lactating
- Hospitalized (inpatient) patients (to be confirmed by expert.) due to GERD as primary or secondary diagnosis
Key Trial Info
Start Date :
January 17 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2019
Estimated Enrollment :
50000 Patients enrolled
Trial Details
Trial ID
NCT03824548
Start Date
January 17 2019
End Date
May 1 2019
Last Update
January 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yuan Na
Beijing, Beijing Municipality, China, 100000